Kalaris Therapeutics, Inc. (KLRS)
$4.04-$0.07 (-1.71%) Today
Srinivas Akkaraju
Diana Brainard - Officer
Vikas Sinha - OfficerKalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Grant or award | 10 | 311,000 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
38 Form 4 filings on record, the earliest from Oct 4, 2024, newest first. Filing history page 2 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Diana Brainard - Officer | Open-market sale | Common Stock | 9,752 | $0.78 | $8K | |
| Edward Miller - Officer | Open-market sale | Common Stock | 635 | $0.78 | $495 | |
| Edward Miller - Officer | Open-market sale | Common Stock | 766 | $0.77 | $588 | |
| Brett R. Hagen - Officer | Open-market sale | Common Stock | 479 | $0.78 | $373 | |
| Brett R. Hagen - Officer | Open-market sale | Common Stock | 486 | $0.77 | $373 | |
| Vikas Sinha - Officer | Open-market sale | Common Stock | 1,546 | $0.78 | $1K | |
| Vikas Sinha - Officer | Open-market sale | Common Stock | 1,882 | $0.77 | $1K | |
| Brett R. Hagen - Officer | Open-market sale | Common Stock | 301 | $0.81 | $245 | |
| Diana Brainard - Officer | Open-market sale | Common Stock | 1,493 | $0.81 | $1K | |
| Edward Miller - Officer | Open-market sale | Common Stock | 377 | $0.81 | $307 | |
| Vikas Sinha - Officer | Open-market sale | Common Stock | 940 | $0.81 | $766 |
This is as far as the anonymous view goes. Create a free account for all 38 KLRS filings on record.
Kalaris Therapeutics, Inc. (KLRS) had 10 insider filings in the last 90 days, with the most recent on 2026-08-28. The full record for KLRS runs to 38 Form 4 filings, the earliest from 2024-10-04. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of KLRS were filed in the last 90 days. 2 purchases are on record for this company.
No insider sales of KLRS were filed in the last 90 days. 20 sales are on record for this company.
This page tracks KLRS Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add KLRS to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
